Travere Therapeutics, Inc. (TVTX) financial statements and ratios from SEC XBRL: revenue $0.6B (TTM), net margin -5.2%, revenue growth 48.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $490.73M |
| Revenue (TTM) | $0.6B |
| Net Margin | -5.2% |
| Operating Margin (TTM) | -6.8% |
| Revenue Growth (YoY) | 48.2% |
| EPS Growth (YoY) | 164.3% |
| EV / EBITDA | 261.5 |
| Price / Book | 249.15 |
| Price / Sales | 10.33 |
| FCF Yield | 0.2% |
| Altman Z-Score | 5.03 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
TVTX overview · TVTX earnings · TVTX KPIs · TVTX documents · TVTX ownership · TVTX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.